Allogene Therapeutics (ALLO)

• Market cap: $396M
• 1 day: -8.25%
• 5 days: -7.80%
• 1 month: 34.04%
• 3 months: 0.00%
• 6 months: -36.15%
• Year to date: -14.09%
• 1 year: -61.27%
• 5 years: -91.43%
• 10 years: -92.44%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Employees: 361

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

153% more call options, than puts

Call options by funds: $446K | Put options by funds: $176K

121% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 14

48% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 42

33% more funds holding in top 10

Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]

11% more funds holding

Funds holding: 155 [Q3] → 172 (+17) [Q4]

9.31% more ownership

Funds ownership: 80.56% [Q3] → 89.87% (+9.31%) [Q4]

15% less capital invested

Capital invested by funds: $472M [Q3] → $401M (-$70.4M) [Q4]